Dexamethasone monotherapy in a frail and chemotherapy-ineligible patient with end-stage multiple myeloma: a case report and literature review
Objective: Multiple Myeloma (MM) is increasing in incidence and for the elderly, survival remains poor, mainly due to poor tolerance to chemotherapy which forms an important component of first-line treatment for MM. No previous study has been found on dexamethasone monotherapy for MM treatment. Cas...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Verduci Editore
2022-11-01
|
| Series: | World Cancer Research Journal |
| Subjects: | |
| Online Access: | https://www.wcrj.net/wp-content/uploads/sites/5/2022/11/e2429.pdf |
| _version_ | 1797980667013758976 |
|---|---|
| author | O. Oey Y. Liu A. Sunjaya |
| author_facet | O. Oey Y. Liu A. Sunjaya |
| author_sort | O. Oey |
| collection | DOAJ |
| description | Objective: Multiple Myeloma (MM) is increasing in incidence and for the elderly, survival remains poor, mainly due to poor tolerance to chemotherapy which forms an important component of first-line treatment for MM. No previous study has been found on dexamethasone monotherapy for MM treatment.
Case Presentation: A 75-year-old female of Chinese descent, previously independent with a background of well-controlled hypertension, type 2 diabetes, hyperlipidemia, and mild Alzheimer’s dementia presented to the general practice with fatigue, left groin pain, decreased appetite and dizziness. She was diagnosed with end-stage MM based on serum protein electrophoresis and skeletal survey and treated with only dexamethasone as a chemotherapeutic agent.
Results: As of February 2022, two years after the diagnosis of end-stage MM and treatment with dexamethasone monotherapy and supportive therapy, the patient remains adherent to her management plan. She remained alive with mild functional decline and preserved renal function.
Conclusions: In addition to managing patients according to the best principles of supportive care, dexamethasone monotherapy may be a good alternative maintenance agent in frail, elderly patients with MM who may not even tolerate attenuated chemotherapy. |
| first_indexed | 2024-04-11T05:58:29Z |
| format | Article |
| id | doaj.art-4826c3d44d2e414184a918f300952dd1 |
| institution | Directory Open Access Journal |
| issn | 2372-3416 |
| language | English |
| last_indexed | 2024-04-11T05:58:29Z |
| publishDate | 2022-11-01 |
| publisher | Verduci Editore |
| record_format | Article |
| series | World Cancer Research Journal |
| spelling | doaj.art-4826c3d44d2e414184a918f300952dd12022-12-22T04:41:49ZengVerduci EditoreWorld Cancer Research Journal2372-34162022-11-01910.32113/wcrj_202211_24292429Dexamethasone monotherapy in a frail and chemotherapy-ineligible patient with end-stage multiple myeloma: a case report and literature reviewO. Oey0Y. Liu1A. Sunjaya2School of Medicine, University of Western Australia, Crawley, Western Australia, AustraliaSchool of Medicine, University of Queensland, Herston, Queensland, AustraliaThe George Institute for Global Health, Sydney, AustraliaObjective: Multiple Myeloma (MM) is increasing in incidence and for the elderly, survival remains poor, mainly due to poor tolerance to chemotherapy which forms an important component of first-line treatment for MM. No previous study has been found on dexamethasone monotherapy for MM treatment. Case Presentation: A 75-year-old female of Chinese descent, previously independent with a background of well-controlled hypertension, type 2 diabetes, hyperlipidemia, and mild Alzheimer’s dementia presented to the general practice with fatigue, left groin pain, decreased appetite and dizziness. She was diagnosed with end-stage MM based on serum protein electrophoresis and skeletal survey and treated with only dexamethasone as a chemotherapeutic agent. Results: As of February 2022, two years after the diagnosis of end-stage MM and treatment with dexamethasone monotherapy and supportive therapy, the patient remains adherent to her management plan. She remained alive with mild functional decline and preserved renal function. Conclusions: In addition to managing patients according to the best principles of supportive care, dexamethasone monotherapy may be a good alternative maintenance agent in frail, elderly patients with MM who may not even tolerate attenuated chemotherapy.https://www.wcrj.net/wp-content/uploads/sites/5/2022/11/e2429.pdfmultiple myelomadexamethasonemonotherapycase report |
| spellingShingle | O. Oey Y. Liu A. Sunjaya Dexamethasone monotherapy in a frail and chemotherapy-ineligible patient with end-stage multiple myeloma: a case report and literature review World Cancer Research Journal multiple myeloma dexamethasone monotherapy case report |
| title | Dexamethasone monotherapy in a frail and chemotherapy-ineligible patient with end-stage multiple myeloma: a case report and literature review |
| title_full | Dexamethasone monotherapy in a frail and chemotherapy-ineligible patient with end-stage multiple myeloma: a case report and literature review |
| title_fullStr | Dexamethasone monotherapy in a frail and chemotherapy-ineligible patient with end-stage multiple myeloma: a case report and literature review |
| title_full_unstemmed | Dexamethasone monotherapy in a frail and chemotherapy-ineligible patient with end-stage multiple myeloma: a case report and literature review |
| title_short | Dexamethasone monotherapy in a frail and chemotherapy-ineligible patient with end-stage multiple myeloma: a case report and literature review |
| title_sort | dexamethasone monotherapy in a frail and chemotherapy ineligible patient with end stage multiple myeloma a case report and literature review |
| topic | multiple myeloma dexamethasone monotherapy case report |
| url | https://www.wcrj.net/wp-content/uploads/sites/5/2022/11/e2429.pdf |
| work_keys_str_mv | AT ooey dexamethasonemonotherapyinafrailandchemotherapyineligiblepatientwithendstagemultiplemyelomaacasereportandliteraturereview AT yliu dexamethasonemonotherapyinafrailandchemotherapyineligiblepatientwithendstagemultiplemyelomaacasereportandliteraturereview AT asunjaya dexamethasonemonotherapyinafrailandchemotherapyineligiblepatientwithendstagemultiplemyelomaacasereportandliteraturereview |